What is the pathophysiology of metamizole (dipyrone)-induced myelosuppression, including agranulocytosis and pancytopenia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 28, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Pathophysiology of Metamizole-Induced Myelosuppression

Metamizole-induced myelosuppression occurs through both immunologic and toxic mechanisms, resulting in agranulocytosis (neutrophil count <500/µL) and rarely pancytopenia, with the reaction being dose-independent but increasing in risk with duration of exposure, and presenting with rapid onset upon re-exposure in previously sensitized patients. 1

Mechanisms of Bone Marrow Suppression

Immunologic Pathway

  • The primary mechanism involves immune-mediated destruction of myeloid precursors, where metamizole or its metabolites act as haptens, triggering antibody formation against neutrophil precursors and mature neutrophils. 1
  • This immunologic reaction explains why agranulocytosis can develop rapidly (within hours to days) upon re-exposure in patients with prior metamizole use, as pre-formed antibodies immediately attack bone marrow cells. 1

Toxic Mechanism

  • A direct toxic effect on bone marrow cells has also been proposed, though the immunologic pathway appears to be the dominant mechanism in most cases. 1
  • The toxic mechanism may contribute to the rare cases of pancytopenia, where all three cell lines (neutrophils, red blood cells, and platelets) are suppressed rather than isolated neutropenia. 2

Bone Marrow Pathology

Histopathologic Findings

  • Bone marrow examination in metamizole-induced agranulocytosis typically reveals either hypocellularity with decreased myeloid precursors or normocellular marrow with maturation arrest in the myeloid series. 3
  • In pediatric cases, bone marrow aspiration showed neutrophil/band maturation delay in the myeloid series with normocellular bone marrow in some patients, while others demonstrated hypocellularity and decreased myeloid precursors. 3
  • In rare cases progressing to pancytopenia, all hematopoietic cell lines are affected, suggesting a more severe immune attack or toxic injury to pluripotent stem cells. 2

Risk Factors and Dose Relationship

Dose-Independent Nature

  • Unlike many drug-induced cytopenias, metamizole-induced agranulocytosis is dose-independent, meaning it can occur at any dose and is not predictable based on the amount consumed. 1
  • However, the risk increases with duration of intake, suggesting cumulative exposure increases the likelihood of sensitization. 1

Re-Exposure Risk

  • In patients with past metamizole exposure, re-exposure may lead to rapid onset of agranulocytosis within hours to days, as opposed to the typical 6-23 day latency period in first-time users. 1
  • This rapid onset upon re-challenge strongly supports an immunologic mechanism with memory B-cell and antibody involvement. 1

Incidence and Epidemiology

Population-Based Risk

  • The incidence of metamizole-induced agranulocytosis ranges from 0.96 cases per million per year to 1:1602 per patient and metamizole prescription, depending on the study methodology. 1, 4
  • A large German statutory health insurance study found a relative risk of 3.03 (95% CI, 2.49-3.69) for drug-induced agranulocytosis and neutropenia compared to non-users. 4
  • A Polish prospective study documented 2 cases of aplastic anemia (but no agranulocytosis) associated with metamizole use over 12 months, yielding an incidence of 0.25 cases of aplastic anemia per 1 million persons per day of treatment. 5

Age and Gender Considerations

  • Female gender and older age are associated with higher incidence, though this may reflect prescription distribution patterns rather than true biological susceptibility. 1
  • The risk in children appears to be lower than in adults, though pediatric cases do occur and can result in prolonged hospitalization. 1, 3

Clinical Pitfalls

Delayed Recognition

  • The dose-independent nature means that even short-term or low-dose use can trigger agranulocytosis, and clinicians must maintain high suspicion even with brief exposures. 1
  • The latency period of days to weeks in first-time users can lead to delayed recognition if the temporal relationship between drug exposure and symptom onset is not carefully evaluated. 1

Absolute Contraindication to Re-Exposure

  • Re-exposure to metamizole must be permanently avoided in any patient with a history of metamizole-induced agranulocytosis, as this can precipitate life-threatening rapid-onset neutropenia. 1
  • This contraindication is absolute and applies even if the initial episode was mild or resolved quickly. 6, 7

References

1
Research

Metamizole-induced agranulocytosis (MIA): a mini review.

Molecular and cellular pediatrics, 2023

5
Research

A prospective study of the incidence of agranulocytosis and aplastic anemia associated with the oral use of metamizole sodium in Poland.

Medical science monitor : international medical journal of experimental and clinical research, 2004

6
Guideline

Metamizol Administration Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

7
Guideline

Metamizol Administration in Perioperative Setting

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

What are the guidelines for using Metamizol (Dipyrone) for pain or fever management?
Can I use metamizol in a 2-month-old infant?
What are the side effects of metamizole in children?
Can methimazole cause hyperthermia (high fever) and pharyngitis (sore throat)?
Can methimazole (Tapazole) cause microcytic anemia?
In an otherwise healthy adult with incidentally discovered mild proteinuria (spot urine protein‑to‑creatinine ratio <300 mg/g), normal blood pressure, normal estimated glomerular filtration rate, and no hematuria or recurrent urinary‑tract infections, is a renal ultrasound indicated?
What is the recommended management for a patient with dense‑deposit disease (DDD) caused by a pathogenic LAMB2 mutation?
In a patient with irritable bowel syndrome, does mucus appear with every bowel movement?
Should a renal ultrasound be performed in a non-diabetic adult with a spot urine protein-to-creatinine ratio of approximately 2300 mg/g?
How do I calculate the maximum safe lidocaine dose per kilogram for local anesthesia, and how does the dose change when lidocaine is combined with epinephrine?
Is a prior history of Raynaud's phenomenon a contraindication to prescribing psychostimulant medications (e.g., methylphenidate, amphetamine‑based agents, lisdexamfetamine)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question